PrEP to Prevent HIV and Promote Sexual Health - Updates, Authorship, and Related Guidelines - Highlights of changes in the May 20, 2022 edition

Sep 27, 2026

Uploaded by Callum

Provides updates, authorship information, and guideline highlights for “PrEP to Prevent HIV and Promote Sexual Health,” current as of May 20, 2022. Incorporates new data since the prior August 2021 edition and adds recommendations for long-acting injectable PrEP using cabotegravir, an integrase strand transfer inhibitor. Identifies intended users as New York State clinicians recommending, initiating, or maintaining PrEP care, and summarizes key clinical sections including access, eligibility, contraindications, regimen selection, protection timing, monitoring, and laboratory testing.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages56

Reading Time2 h 21 min

AccessFree to download

Purpose of This Guideline

Goals

PrEP Access and Coverage

PrEP for Individuals at Risk of Acquiring HIV

PrEP Candidates

PrEP for Adolescents

Assessment and Counseling Before PrEP Initiation

PrEP in Comprehensive HIV Prevention Planning

Contraindications to PrEP Use

PrEP Failure

Choosing and Prescribing a PrEP Regimen

Comparison of Available Regimens

Time to Protection

Engagement in Care

Adherence

PrEP During Pregnancy

Laboratory Testing Before PrEP Initiation

HIV Testing

PrEP to Prevent HIV and Promote Sexual Health Updates, Authorship, and Related Guidelines Date of current publication Highlights of changes, additions, and updates in the May 20, 2022 edition Intended users Lead author Writing group Author and writing group conflict of interest disclosures Date of original publication Committee Developer and funder Development process Related NYSDOH AI guidelines May 20, 2022 Updates were made to incorporate data that are new since the previous edition was published in Aug. 2021 and to include recommendations for the long-acting injectable formulation of the integrase strand transfer inhibitor cabotegravir as PrEP New York State clinicians who are recommending, initiating, or maintaining PrEP care for individuals at risk of acquiring HIV Rona M. Vail, MD Steven M. Fine, MD, PhD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD; Asa Radix, MD, MPH, PhD; Jessica Rodrigues; Christopher J. Hoffmann, MD, MPH; Lyn C. Stevens, MS, NP, ACRN; Charles J. Gonzalez, MD Joseph P. McGowan, MD, FACP, FIDSA: Institutional Pharma grant recipient/support, clinical trial; Gilead October 10, 2019 Medical Care Criteria Committee New York State Department of Health AIDS Institute (NYSDOH AI) See Supplement: Guideline Development and Recommendation Ratings • Diagnosis and Management of Acute HIV Infection • Hepatitis C Virus Screening, Testing, and Diagnosis in Adults • HIV Testing • Prevention and Management of Hepatitis B Virus Infection in Adults With HIV • PEP to Prevent HIV Infection • Rapid ART Initiation • Selecting an Initial ART Regimen • Substance Use Harm Reduction in Medical Care • Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults NYSDOH AI Guidance • Resource: ART Drug-Drug Interactions • GOALS Framework for Sexual History Taking in Primary Care • U=U Guidance for Implementation in Clinical Settings PrEP to Prevent HIV and Promote Sexual Health Date of current publication: May 20, 2022 Lead author: Rona M. Vail, MD Writing group: Steven M. Fine, MD, PhD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD; Asa Radix, MD, MPH, PhD; Jessica Rodrigues; Christopher J. Hoffmann, MD, MPH; Lyn C. Stevens, MS, NP, ACRN; Charles J. Gonzalez, MD Committee: Medical Care Criteria Committee Date of original publication: October 10, 2019 Contents Purpose of This Guideline .......................................................................................................................................................... 3 Goals ....................................................................................................................................................................................... 3 PrEP Access and Coverage ...................................................................................................................................................... 3 PrEP for Individuals at Risk of Acquiring HIV.............................................................................................................................. 5 PrEP Candidates ...................................................................................................................................................................... 5 PrEP for Adolescents ............................................................................................................................................................... 8 Assessment and Counseling Before PrEP Initiation ................................................................................................................ 8 PrEP in Comprehensive HIV Prevention Planning ................................................................................................................. 10 Contraindications to PrEP Use ..............................................................................................................

FAQs

What changes were made in the May 20, 2022 edition of the guideline?

Updates incorporate data new since the August 2021 edition and include recommendations for long-acting injectable cabotegravir as PrEP.

Who is the intended audience for this PrEP guideline?

New York State clinicians who recommend, initiate, or maintain PrEP care for individuals at risk of acquiring HIV.

Which major topics does the guideline cover for PrEP implementation?

It includes access and coverage, eligibility (including candidates and adolescents), counseling and assessment before initiation, contraindications and PrEP failure, regimen selection and comparisons, time to protection, engagement in care, adherence, pregnancy considerations, and laboratory testing including HIV testing.

Sep 27, 2026

Uploaded by Callum